NCT04911127View on ClinicalTrials.gov

Therapeutic Response of Cannabidiol in Rheumatoid Arthritis

PHASE1CompletedINTERVENTIONAL
Enrollment

67

Participants

Timeline

Start Date

October 5, 2021

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2023

Conditions
Rheumatoid ArthritisCannabis
Interventions
DRUG

200mg Cannabidiol by capsules twice daily

200mg twice daily via 50mg capsules

DRUG

400mg Cannabidiol by capsules twice daily

400mg twice daily via 50mg capsules

DRUG

Placebo capsules

MCT oil capsules as placebo for CBD

Trial Locations (1)

90095

UCLA David Geffen School of Medicine, Division of Rheumatology, Los Angeles

All Listed Sponsors
lead

University of California, Los Angeles

OTHER

NCT04911127 - Therapeutic Response of Cannabidiol in Rheumatoid Arthritis | Biotech Hunter | Biotech Hunter